Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Werewolf Therapeutics (HOWL) Revenue (2022 - 2024)

Werewolf Therapeutics (HOWL) has disclosed Revenue for 3 consecutive years, with $15000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Revenue fell 99.03% to $15000.0 in Q4 2024 year-over-year; TTM through Sep 2025 was $15000.0, a 99.56% decrease, with the full-year FY2024 number at $1.9 million, down 90.47% from a year prior.
  • Revenue was $15000.0 for Q4 2024 at Werewolf Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $8.1 million in Q2 2023 to a low of $15000.0 in Q4 2024.
  • A 3-year average of $3.8 million and a median of $4.3 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: surged 94.82% in 2023, then plummeted 99.03% in 2024.
  • Werewolf Therapeutics' Revenue stood at $7.3 million in 2022, then tumbled by 78.81% to $1.5 million in 2023, then tumbled by 99.03% to $15000.0 in 2024.
  • Per Business Quant, the three most recent readings for HOWL's Revenue are $15000.0 (Q4 2024), $1.1 million (Q2 2024), and $742000.0 (Q1 2024).